PET Scan Denied by Insurance? How to Appeal

Positron emission tomography (PET) scans are among the most commonly denied diagnostic imaging studies in health insurance. Whether the denial is for oncology staging, cardiac viability assessment, or neurological evaluation, PET scan denials are frequently overturned on appeal when the right clinical evidence and regulatory citations are presented. This guide covers the specific arguments that work for each clinical indication.

Why Insurers Deny PET Scans

PET scan denials cluster around several predictable denial patterns.

"CT must be performed first" step imaging requirements. Many insurers require CT before approving PET, claiming PET is a "second-step" imaging study. This argument misunderstands the complementary roles of the two tests. CT provides anatomical detail; PET provides metabolic and biological activity data. For lymphoma staging, NCCN Guidelines designate FDG-PET/CT (combined study) as the preferred initial staging modality — separate from and not replaceable by CT alone. Your physician's letter should cite the specific NCCN guideline indicating that PET is the recommended first study for your cancer type, not a follow-on to CT.

"Not medically necessary" for non-covered or non-approved indications. The insurer's reviewer concluded that your clinical scenario does not meet their internal criteria. Request the insurer's clinical policy bulletin to understand the exact criteria applied. For most solid tumor oncology indications, CMS NCD 220.6 and ACR Appropriateness Criteria provide the authoritative standards that commercial insurers typically follow.

"Frequency limitation" denials. Some plans limit PET to one study per year. If you need a restaging study within 12 months, document why the additional study is medically necessary — progressive disease, change in clinical status requiring reassessment, or a distinct clinical event requiring its own staging evaluation.

"Investigational/experimental" classification. For established oncology and cardiac indications, FDG-PET has extensive peer-reviewed evidence, FDA clearance, and CMS NCD coverage. It is not experimental. Cite CMS NCD 220.6 and the applicable NCCN guideline category (Category 1 evidence for most major tumor types).

Non-covered indication disputes. Medicare NCD 220.6 covers specific solid tumor types and not others (except under Coverage with Evidence Development). Commercial plans follow varying criteria. Your appeal must cite the specific indication code and align it with the appropriate coverage basis.

How to Appeal a PET Scan Denial

Step 1: Identify the Specific Denial Basis and Request Clinical Criteria

Obtain the denial letter's specific reason code and the insurer's PET scan clinical coverage policy. For Medicare patients, CMS NCD 220.6 is publicly available and provides the definitive coverage framework. For commercial plans, request the specific clinical policy bulletin that governed your denial. Under ERISA (29 U.S.C. § 1133) and ACA regulations, you are entitled to these documents.

Step 2: Establish the Clinical Indication with Precision

Your ordering physician's letter must document: the specific cancer type (by primary site), histology, and current disease stage; whether the PET is for initial staging, restaging, monitoring treatment response, or suspected recurrence; and how the PET result will change clinical management. The last point is critical — reviewers are less likely to sustain a denial when the physician clearly explains that PET results will directly determine treatment selection.

Step 3: Cite CMS NCD 220.6 for Your Tumor Type

CMS NCD 220.6 covers FDG-PET for diagnosis, staging, and restaging of: head and neck cancers, esophageal cancer, colorectal cancer, lymphoma (Hodgkin's and NHL), melanoma, lung cancer (NSCLC, SCLC), ovarian cancer, cervical cancer, brain tumors, thyroid cancer, breast cancer (restaging and response monitoring), and prostate cancer (PSA recurrence). If your tumor type is on this list, cite the specific NCD provision in your appeal.

Step 4: Cite ACR Appropriateness Criteria and NCCN Guidelines

The American College of Radiology Appropriateness Criteria for FDG-PET and the NCCN Clinical Practice Guidelines in Oncology (nccn.org, free with registration) are the most comprehensive evidence-based references for PET indications. Cite the specific ACR appropriateness rating ("Usually Appropriate" for your clinical scenario) and the NCCN recommendation category (Category 1 for the strongest evidence base).

Step 5: Address the Step Imaging Argument

If denied for failure to obtain CT first, your appeal should explicitly state: "PET and CT provide complementary information that cannot substitute for each other. [NCCN Guideline X] designates PET-CT as the preferred initial staging modality for [cancer type], not as a follow-on to CT. Requiring CT first would delay staging and clinical decision-making without clinical benefit."

Step 6: Request External Independent Review: Complete Guide" class="auto-link">External Review

If the internal appeal is denied, request independent external review at no cost under the ACA. External reviewers applying ACR Appropriateness Criteria and NCCN guidelines frequently reverse PET scan denials for covered oncology indications, particularly when the ordering physician's letter is specific about how results will change clinical management.

What to Include in Your Appeal

• Denial letter with the specific denial reason and clinical criteria applied
• Ordering physician's letter documenting the cancer type, clinical indication (initial staging/restaging/surveillance), and how PET results will change clinical management
• CMS NCD 220.6 citation for the specific tumor type, if applicable
• NCCN Guideline excerpt showing PET-CT as the recommended study for the specific clinical scenario (include the Category of Evidence)
• ACR Appropriateness Criteria rating for the specific clinical scenario

Fight Back With ClaimBack

PET scan denials are reversed when the appeal cites CMS NCD 220.6, ACR Appropriateness Criteria, and NCCN guidelines for your specific oncology indication. ClaimBack generates a professional appeal letter in 3 minutes. Start your free claim analysis → Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal